

SCIENTIFIC REPORTS



OPEN

Low amounts of dietary fibre increase *in vitro* production of short-chain fatty acids without changing human colonic microbiota structure

Daisuke Sasaki¹, Kengo Sasaki¹, Naoko Ikuta², Takahiro Yasuda³, Itsuko Fukuda^{4,5}, Akihiko Kondo^{1,6} & Ro Osawa^{4,5}

This study investigated the effect of various prebiotics (indigestible dextrin, α -cyclodextrin, and dextran) on human colonic microbiota at a dosage corresponding to a daily intake of 6 g of prebiotics per person (0.2% of dietary intake). We used an *in vitro* human colonic microbiota model based on batch fermentation starting from a faecal inoculum. Bacterial 16S rRNA gene sequence analysis showed that addition of 0.2% prebiotics did not change the diversity and composition of colonic microbiota. This finding coincided with results from a clinical study showing that the microbiota composition of human faecal samples remained unchanged following administration of 6 g of prebiotics over seven days. However, compared to absence of prebiotics, their addition reduced the pH and increased the generation of acetate and propionate in the *in vitro* system. Thus, even at such relatively low amounts, prebiotics appear capable of activating the metabolism of colonic microbiota.

Prebiotics are defined as “a selectively fermented ingredient that results in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon host health”¹. Dietary prebiotics are not digested in the human small intestine and enter the colon, where they are fermented by the gut microflora^{2,3}.

Indigestible dextrans are composed of a glucose polymer and are considered as prebiotic fibre functional ingredients². Short-chain fatty acids (SCFAs) are fermentation products of indigestible dextrin that exert important health functions, such as regulating the absorption of water and minerals and reducing colonic pH to inhibit potential pathogens and promote growth of beneficial bacteria³. Recently, an *in vitro* study demonstrated that at a concentration of 1.25% (wt/vol), dextrans from maize or wheat stimulate the growth of beneficial microorganisms such as those from the genera *Bifidobacterium* and *Lactobacillus*, and the phylum Bacteroidetes^{4–6}. Cyclodextrins (CDs) are industrially produced enzyme-modified starch derivatives that can be used also as food additives⁷. CDs are cyclic oligosaccharides consisting of six (α CD), seven (β CD), or eight (γ CD) α -1,4-linked glycopyranose units, with a hydrophilic hydroxyl group on their outer surface and a hydrophobic cavity in their centre. In these CDs, α CD is widely used as a water-soluble dietary fibre⁸. Addition of 1.5% α CD to mice has been shown to decrease the numbers of caecal bacteria belonging to the genus *Clostridium*⁹. In contrast, dextran is produced by lactic acid bacteria of the genera *Leuconostoc*, *Streptococcus*, *Lactococcus*, and *Lactobacillus*¹⁰. *In vitro* experiments

¹Graduate School of Science, Technology and Innovation, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, Hyogo, 657-8501, Japan. ²Graduate School of Medicine, Kobe University, 7-5-2 Kusunoki-cho Chuo-ku, Kobe, Hyogo, 650-0017, Japan. ³Clinical & Translational Research Center, Kobe University Hospital, 7-5-2 Kusunoki-cho Chuo-ku, Kobe, Hyogo, 650-0017, Japan. ⁴Department of Bioresource Science, Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, Hyogo, 657-8501, Japan. ⁵Research Center for Food Safety and Security, Graduate School of Agricultural Science, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe, Hyogo, 657-8501, Japan. ⁶RIKEN Center for Sustainable Resource Science, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan. Daisuke Sasaki and Kengo Sasaki contributed equally to this work. Correspondence and requests for materials should be addressed to K.S. (email: sikengo@people.kobe-u.ac.jp)

Prebiotics	Glucosidic linkages	Molecular weight
Indigestible dextrin (DEX)	α -1,4*, α -1,6, α -1,2, α -1,3	1,800–2,000
α -Cyclodextrin (α CD) [#]	α -1,4*	972
Dextran (DXR)	α -1,6*, α -1,4	32,000–45,000

Table 1. Prebiotics used in this study. *Predominant linkage. [#] α -cyclodextrin is a cyclic oligosaccharide consisting of six glucopyranose units.

have shown that administration of 1-kDa dextrans (linear and α -1,2 branched) at a concentration of 1% could selectively increase the number of bacterial cells belonging to the genus *Bifidobacterium*^{11,12}. However, given that the daily Japanese human diet is approximately 3 L (3,000 g)^{13,14}, the amounts of prebiotics administered in previous studies (same or more than 1%, i.e., ≥ 30 g/day) were too high and should be decreased to reflect a more realistic dosage.

In vitro models do not pose the same ethical constraints as *in vivo* human trials and allow dynamic sampling to study microbial activity *in vivo*. Thus, *in vitro* batch fermentation systems inoculated with human faecal matter to mimic the human digestive tract environment have been applied to measure production of SCFAs¹⁵ and test the modulatory effect of potential prebiotics on human gut microbiota^{16–18}. By carefully constructing the necessary anaerobic conditions, we previously developed an *in vitro* batch fermentation system (hereafter referred to as Kobe University Human Intestinal Microbiota Model, KUHIMM) that is capable of hosting more than 500 microbial species found in a human faecal inoculum and can effectively mimic human colonic microbiota¹³. The number of microbial species in this system was similar to the that (400–1000) previously reported in human faecal samples^{19,20}. Our KUHIMM was able to reproduce the bifidogenic effects of prebiotic materials (i.e., fructo-, galacto-, iso-malto- and xylo-oligosaccharides), in line with the results from human clinical trials²¹.

The aim of this study was to assess the effect of relatively low amounts of three different prebiotics, i.e., indigestible dextrin (DEX), α -cyclodextrin (α CD), and dextran (DXR), on human colonic microbiota using our KUHIMM system (Table 1). The prebiotic concentration was set to 0.2%, corresponding to 6 g prebiotics per 3 L of daily dietary intake^{13,14}, and was sufficiently low to avoid the occurrence of any intestinal discomfort. The bacterial composition in the KUHIMM following prebiotic treatment was evaluated by next-generation sequencing (NGS) and compared with that in the absence of prebiotics. Similarly, we compared also pH changes and production of SCFAs. In addition, a small human trial was performed with a daily intake of 6 g of DEX or α CD to compare the microbiota composition in actual human faeces with that in the KUHIMM.

Results

Prebiotics reduce the pH in the KUHIMM. The KUHIMM was operated by adding 0.2% DEX, α CD, or DXR, and each of eight human faecal samples (designated as F26, F40, F62, M27, M37, M38, M39, and M60) was used as the inoculum. A control that included no prebiotics was also prepared. During the fermentation, pH transition occurred due to production of mainly SCFAs and ammonia (Supplementary Fig. S1). Continuous monitoring (Fig. 1) revealed an overall reduction in pH in the later phase of fermentation in the presence of prebiotics compared to the control. The lower pH reflected changes in environmental conditions resulting from the interplay between prebiotics and human gut microbiota.

Addition of 0.2% prebiotics does not alter microbial diversity. DNA was extracted from human faeces and from KUHIMM samples collected at 30 h of fermentation. In all KUHIMM samples, eubacterial copy numbers, evaluated by quantitative PCR, reached 9.15×10^{10} copies/mL (Supplementary Table S1) and were comparable to the reported cell densities in human faeces (approximately 10^{11} /wet-g)²².

NGS was used for bacterial 16S rRNA gene sequence analysis of faecal samples and corresponding cultures with and without prebiotics. In total, 5,922,873 quality reads with an average of 148,072 reads were obtained (Table 2). The numbers of operational taxonomic units (OTUs) and α -diversity values (Chao1, Shannon index, and Simpson index) were not lower in cultures treated with or without prebiotics than in faecal samples (Kruskal-Wallis test). Thus, as described previously, bacterial numbers in human faeces were maintained in the corresponding cultures of our KUHIMM¹³. There were fewer OTUs in cultures treated with DEX and α CD than in control cultures ($P < 0.05$, Kruskal-Wallis test); however, OTU numbers were higher in the presence of DXR than in the absence of prebiotics ($P < 0.05$, Kruskal-Wallis test). Chao1 values, which indicate species richness, were lower in cultures with DEX and α CD than in controls ($P < 0.05$, Kruskal-Wallis test), but were not significantly different between DXR-treated cultures and controls ($P > 0.05$, Kruskal-Wallis test). Moreover, the Shannon and Simpson indexes were not significantly different between cultures containing prebiotics and controls ($P > 0.05$, Kruskal-Wallis test). Therefore, species diversity in our KUHIMM did not change following addition of 0.2% prebiotics.

Addition of 0.2% prebiotics does not change microbial composition. Principal coordinate analysis (PCoA) of unweighted UniFrac distances revealed that microbiota in faecal samples shifted in the same direction as in the corresponding cultures without prebiotics ($P = 0.454$, multivariate analysis of variance (MANOVA)) (Fig. 2). No significant changes were detected between the microbiota of cultures with and without prebiotics (DEX: $P = 0.571$; α CD: $P = 0.986$; DXR: $P = 0.996$, MANOVA).

Bacterial composition was compared in cultures with and without prebiotics (Fig. 3). Approximately 99% of the total bacterial abundance was assigned to five phyla Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, and Proteobacteria. Relative abundances of the genera *Bifidobacterium*, *Collinsella*, *Bacteroides*, *Parabacteroides*, *Prevotella*, *Enterococcus*, *Lactococcus*, *Streptococcus*, uncultured Clostridiaceae, *Clostridium*,




Figure 1. pH profiles obtained during fermentation in the KUHIMM with and without 0.2% prebiotics. Fermentation was initiated by inoculating each of the human faecal samples (designated as F26, F40, F62, M27, M37, M38, M39, and M60). pH profiles without prebiotics (CUL) and with 0.2% indigestible dextrin (DEX), α -cyclodextrin (α CD), or dextran (DXR) are shown with black, blue, red, and green lines, respectively.

	KUHIMM (n = 8)				
	FEC	CUL	DEX	α CD	DXR
Read counts	123,622 \pm 29,146	166,869 \pm 35,152	151,911 \pm 30,120	79,656 \pm 12,693	218,300 \pm 42,461
Observed OTUs	1,168 \pm 291	1,525 \pm 204*	1,294 \pm 167 [#]	1,083 \pm 151 ^{##}	1,954 \pm 326 [#]
Chao1	1,834 \pm 441	2,362 \pm 321*	2,024 \pm 253 [#]	1,896 \pm 255 [#]	2,751 \pm 510
Shannon index	5.39 \pm 0.26	5.24 \pm 0.25	5.14 \pm 0.32	5.10 \pm 0.27	5.31 \pm 0.36
Simpson index	0.94 \pm 0.01	0.94 \pm 0.02	0.94 \pm 0.02	0.93 \pm 0.01	0.94 \pm 0.02

Table 2. Summary of 16S rRNA gene sequencing data and α -diversity values (Chao1 estimator, Shannon index, and Simpson index). Eight human faeces samples (FEC), corresponding cultures (CUL), and corresponding cultures treated with 0.2% indigestible dextrin (DEX), α -cyclodextrin (α CD), or dextran (DXR) were sampled at 30 h of fermentation. The values show the mean \pm standard deviation. Statistical differences between samples were evaluated with respect to observed operational taxonomic units (OTUs), Chao1 estimator, Shannon index, and Simpson index. Asterisks (*) indicate significant differences between faeces from eight healthy subjects and corresponding cultures without or with prebiotics (* P < 0.05 and ** P < 0.01, Kruskal-Wallis test). Pounds ([#]) indicate significant differences between cultures with and without prebiotics ([#] P < 0.05 and ^{##} P < 0.01, Kruskal-Wallis test).

uncultured Lachnospiraceae, *Blautia*, *Coprococcus*, *Dorea*, uncultured Peptostreptococcaceae, uncultured Ruminococcaceae, *Faecalibacterium*, *Oscillospira*, *Ruminococcus*, *Acidaminococcus*, *Dialister*, *Megamonas*, *Megasphaera*, *Phascolarctobacterium*, uncultured Erysipelotrichaceae, *Fusobacterium*, *Sutterella*, *Succinivibrio*, uncultured Enterobacteriaceae, and *Citrobacter* did not differ significantly between cultures with and without prebiotics (P < 0.05, Kruskal-Wallis test). Thus, bacterial compositions in our KUHIMM did not change following addition of 0.2% prebiotics.

Addition of 0.2% prebiotics increases production of SCFAs. SCFAs are the end-products of microbial fermentation in the colon and act as signalling molecules between gut microbiota and the host, with important implications for host health^{3,23}. The effect of adding 0.2% prebiotics on SCFA production in the KUHIMM was evaluated (Fig. 4). At 30 h after initiating fermentation and in the absence of prebiotics, the production of acetate, propionate, and butyrate was 101.0 \pm 23.2 mM, 35.9 \pm 9.69 mM, and 26.9 \pm 11.5 mM, respectively. The concentration of lactate was lower than 0.02 mM. Interestingly, the concentrations of acetate and propionate were significantly higher following addition of prebiotics (P < 0.05, Dunnett test), whereas that of butyrate remained unchanged.

The effect on faecal microbiota composition is confirmed by a human intervention study. To compare the effect of a daily intake of dietary fibre on healthy human microbiota with data from the KUHIMM, we performed a preliminary, small scale, open-label clinical study. To this end, we investigated each faecal sample obtained from four human volunteers (F26, M37, M38, and M39), who ate a daily amount of 6 g of DEX or α CD for seven days. Before eating prebiotics, the composition of human gut microbiota was calibrated by drinking 200 mL of water for 14 days (washout-1) (Supplementary Fig. S2). Faecal samples were collected four times during the final days of eating prebiotics and drinking water. NGS analysis showed that species (OTU) numbers and microbial diversity (α -diversity) did not differ significantly between faeces collected after eating prebiotics or after




Figure 2. Principal coordinate analysis (PCoA) of 16S metagenomics data of bacterial species in eight human volunteers' faeces (designated as F26, F40, F62, M27, M37, M38, M39, and M60) and corresponding cultures with and without 0.2% prebiotics: indigestible dextrin (DEX), α -cyclodextrin (α CD), and dextran (DXR). Cultures were sampled at 30 h after initiation of fermentation. (a) Human faeces (FEC); (b) corresponding culture without prebiotics (CUL); (c) corresponding culture with 0.2% DEX; (d) corresponding culture with α CD; (e) corresponding culture with DXR.




Figure 3. Genus-level compositional view of bacteria in cultures after 30 h of fermentation. One each of eight human faecal samples (designated as F26, F40, F62, M27, M37, M38, M39, and M60) was used as the inoculum in each KUHIMM. Samples were obtained from fermentation cultures without prebiotics (CUL) and cultures with 0.2% indigestible dextrin (DEX), α -cyclodextrin (α CD), or dextran (DXR) at 30 h after initiation of fermentation. Genera of lower abundance ($<1.0\%$) and lower similarity ($<97\%$) were included in Others and Uncultured Bacteria, respectively.

drinking water ($P > 0.05$, Kruskal-Wallis test) (Table 3). Similar to the results in the KUHIMM, PCoA analysis revealed that microbiota compositions clustered equally in the four faecal samples (two with prebiotics and two without) from the same individual (Fig. 5). Thus, eating 6 g of DEX or α CD for seven days did not significantly affect the microbiota composition in the human colon. The results obtained in the human intervention study coincided with the findings in the KUHIMM.




Figure 4. Changes in production of (a) acetate, (b) propionate, and (c) butyrate at 30 h after initiation of fermentation in the KUHIMM supplemented with 0.2% prebiotics: indigestible dextrin (DEX), α -cyclodextrin (α CD), and dextran (DXR). Changes are presented as the ratio of the concentrations in the KUHIMM with prebiotics normalised to those without prebiotics. Asterisks (*) indicate significantly different values ($*P < 0.05$ and $**P < 0.01$) ($n = 8$) using Dunnett test. Error bars show the standard deviation of the mean.

	Human intervention study ($n = 4$)			
	washout-1	α CD	washout-2	DEX
Read counts	116,239 \pm 38,393	129,196 \pm 42,459	138,811 \pm 48,413	125,079 \pm 42,432
Observed OTUs	1,518 \pm 288	1,548 \pm 471	1,534 \pm 460	1,620 \pm 527
Chao1	2,416 \pm 558	2,459 \pm 675	2,457 \pm 538	2,530 \pm 752
Shannon index	5.70 \pm 0.36	5.35 \pm 0.69	5.53 \pm 0.70	5.64 \pm 0.67
Simpson index	0.95 \pm 0.01	0.92 \pm 0.04	0.94 \pm 0.03	0.95 \pm 0.02

Table 3. Summary of 16S rRNA gene sequencing data and α -diversity values (Chao1, Shannon index, and Simpson index) in faecal samples obtained from a human intervention study. Four human volunteers participated in this study. Faecal samples were obtained after the subjects drank water for 14 days (washout-1 or washout-2) and ate α -cyclodextrin (α CD) or indigestible dextrin (DEX) for seven days. The values show the mean \pm standard deviation. No statistical difference was detected between faecal samples (washout-1, α CD, washout-2, and DEX) in terms of observed operational taxonomic units (OTUs), Chao1, Shannon index, and Simpson index (Kruskal-Wallis test).

Discussion

The aim of the present study was to investigate the impact of a low dosage (0.2%) of prebiotics (DEX, α CD, or DXR) on human colonic microbial ecology and metabolic end-products using an *in vitro* batch fermentation system, KUHIMM. We mimicked a daily intake of 6 g of prebiotics, assuming that the total Japanese human daily intake of foods and beverages is 3000 g¹⁴. Our *in vitro* and *in vivo* experiments suggest that a low dosage of prebiotics did not significantly affect the colonic microbiota composition. This contrasts with previous reports where a higher intake of prebiotics such as wheat dextrin (10–20 g/day in humans)^{24,25}, α CD (1.5% in mice)⁹, and DXR (1–10% in an *in vitro* system)^{26,27} substantially changed the colonic microbiota composition. However, addition




Figure 5. Principal coordinate analysis (PCoA) of 16S metagenomic data of bacterial species in human faecal samples obtained from a human intervention study. Four human volunteers (designated as F26, M37, M38, and M39) participated in this study. In one subject, two faecal samples (designated as washout-1 (plot 1) and washout-2 (plot 3)) were collected after the subjects drank water for 14 days and another two faecal samples (designated as α CD (plot 2) and DEX (plot 4)) were collected after the subjects consumed α -cyclodextrin or indigestible dextrin, respectively, for seven days. In addition, PCoA plots, which were obtained from the KUHIMM without prebiotics (CUL (plot b)) and with indigestible dextrin (DEX (plot c)) or α -cyclodextrin (α CD (plot d)) (already shown in Fig. 2), are also presented. Faecal samples from the subjects participating in the human intervention study were used to inoculate the cultures in the KUHIMM.

of prebiotics reduced the pH and promoted the generation of acetate and propionate even at low concentrations, as revealed by the *in vitro* experiments.

This increase in acetate and propionate is in line with previous findings on the administration of wheat dextrin²⁸, α CD²⁹, and DXR²⁶. Bacteria belonging to the phylum Bacteroidetes, which make up a large proportion of the intestinal microbiota, are known to produce mainly propionate along with acetate^{30–32}. The phylum Bacteroidetes harbours a very broad saccharolytic potential³³ and plays an important role in fermenting indigestible carbohydrates in the proximal colon³⁰. Here, the relative abundance of this phylum correlated positively with the prevalence of propionate among total SCFAs (Supplementary Fig. S3), as observed previously in human faeces^{34,35}. In addition, bacteria belonging to the genus *Bifidobacterium*, which were abundant in the phylum Actinobacteria in our system, are known to produce acetate^{36,37}. Not surprisingly, the relative abundance of Actinobacteria showed a positive correlation with the proportion of acetate among total SCFAs (Supplementary Fig. S3). However, the cell abundance of phyla Bacteroidetes and Actinobacteria did not show a significant difference between control cultures and cultures with prebiotics, considering that the total number of eubacteria and relative abundance of these phyla were similar in the cultures, although cell abundance reportedly correlates with metabolic activity, i.e., rates of fermentation³⁴. Therefore, it was expected that prebiotics such as DEX, α CD, and DXR could potentially increase the metabolic activity of bacteria belonging to the phyla Bacteroidetes and Actinobacteria, irrespective of the lack of increase in growth at low dosage amounts. In contrast, bacteria belonging to the phylum Firmicutes are known to produce butyrate as the primary metabolic end-product³⁰. Thus, the relative abundance of the phylum Firmicutes correlated positively with the proportion of butyrate among total SCFAs (Supplementary Fig. S3). Low amounts of the tested prebiotics had no significant effect on the metabolic activity of bacteria belonging to the phylum Firmicutes.

Epithelial cells and immune cells are missing in *in vitro* models¹⁵. Addition of enterocytes and/or immune cells to an *in vitro* model will broaden the current understanding of the effect of different microbial metabolite patterns on host cells. In summary, the KUHIMM was able to capture an increase in SCFA production due to increased metabolic activity of human colonic microbiota, with no accompanying alteration in microbial composition, in response to a low-dosage supply of prebiotics. These results suggest that the positive effect of prebiotics seen *in vitro* using our human colonic microbiota model can be achieved also *in vivo* in human subjects upon administration of 6 g of prebiotics per day, although increased SCFA production is difficult to detect in the human intestine. This amount represents a realistic intake and does not pose a burden on a person's eating habits.

Materials and Methods

Faecal sample collection from human volunteers. Faecal samples were obtained from eight Japanese healthy human volunteers, who had not been treated with antibiotics for more than two months prior to the experiment. All participants were recruited according to the inclusion criteria, which comprised an age of 20 to

65 years, being Japanese, non-smoking status, good health and physical condition. The exclusion criteria included significant clinical deviation from normal as determined by investigators; history or suspicion of diabetes, liver disease, kidney disease, or having a food allergy; or taking supplemental dietary fibre or lipid-lowering medications. Volunteers were designated as F26 (female, age 26), F40 (female, age 40), F63 (female, age 63), M27 (male, age 27), M37 (male, age 37), M38 (male, age 38), M39 (male, age 39), and M60 (male, age 60). All subjects provided written informed consent prior to specimen collection. The study was performed in accordance with the guidelines of Kobe University Hospital, and approved by the institutional ethics review board of Kobe University. All methods in this study were in accordance with the Declaration of Helsinki. The authors have no financial or personal relationships that could inappropriately influence this research.

Faecal samples were immediately collected in an anaerobic culture swab (212550 BD BBL Culture Swab; Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and used within 24 h.

Operation of the KUHIMM with and without prebiotics. The KUHIMM was operated using a multi-channel fermenter (Bio Jr.8; ABLE, Tokyo, Japan), as described previously^{13,21} with some modifications. The KUHIMM consisted of eight parallel and independent vessels. Each vessel contained 100 mL of Gifu Anaerobic Medium (GAM; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan). The medium was autoclaved at 115 °C for 15 min and the initial pH was adjusted to 6.5. Anaerobic conditions in the vessel were achieved by purging with a mixture of N₂ and CO₂ (80:20; 15 mL/min) that was filter-sterilised through a 0.2-µm PTFE membrane (Pall Corporation, Port Washington, NY, USA) at 37 °C for 1 h prior to cultivation. To prepare the inoculum, the faecal sample in the swab was suspended in 2.0 mL of 0.1 M phosphate buffer (pH 6.5, consisting of 0.2 M NaH₂PO₄ and 0.1 M Na₂HPO₄) supplemented with 1.0% L-ascorbic acid (Wako Pure Chemical Industries, Osaka, Japan).

Cultivations were initiated by inoculating one faecal suspension (100 µL) into each vessel. During fermentation at 37 °C, the culture broth was stirred at 300 rpm with a magnetic stirrer and continuously purged with a filter-sterilised mixture of gas to maintain anaerobic conditions. Aliquots (1 mL) of culture broth were sampled from the vessel at 30 h after the initiation of cultivation. Faeces and culture broth samples were stored at -20 °C until use.

To evaluate the effect of prebiotics (Table 1), one type of prebiotics was added into one of the vessels at a final concentration of 2.0 g/L (0.2% per 100-mL vessel) prior to fermentation. The following prebiotics were used: DEX (Fibersol-2; Matsutani Chemical Industry Co., Ltd., Hyogo, Japan), αCD (Cyclochem Co., Ltd., Hyogo, Japan), and DXR (Dextran 40,000; Wako Pure Chemical Industries). A control vessel without prebiotics was prepared.

Human intervention study. All participants were recruited according to the inclusion criteria, which comprised an age of 20 to 50 years, being Japanese, non-smoking status, good health and physical condition, and a fasting triglyceride level of 120 mg/dL to 199 mg/dL. The exclusion criteria included significant clinical deviation from normal as determined by investigators; history or suspicion of diabetes, liver disease, kidney disease, or having a food allergy; or taking supplemental dietary fibre or lipid-lowering medications. A human intervention study was conducted on four volunteers (F26, M37, M38, and M39) (Supplementary Fig. S2). At first, the volunteer drank water (200 mL) twice a day for 14 days (days 1–14, washout-1), and faeces were sampled using the swab on day 14. Then, the volunteer ate 3.0 g of αCD dissolved in water (200 mL) twice a day (6.0 g/day) for seven days (days 15–21), and faeces were sampled on day 21. Next, the volunteer drank water (200 mL) twice a day for 14 days (days 22–35, washout-2) again, and faeces were sampled on day 35. Thereafter, the volunteer ate 3.0 g of DEX dissolved in water (200 mL) twice a day (6.0 g/day) for seven days (days 36–42), and faeces were sampled on day 42. During the study, the four volunteers avoided drinking alcohol or consuming other dietary fibres.

The study was performed in accordance with the guidelines of Kobe University Hospital, and approved by the institutional ethics review board of Kobe University. All methods in this study were in accordance with the Declaration of Helsinki and the approved guidelines by the Medical Ethics Committee at Kobe University (research code; 290001, approved date; 21 Mar 2017). The authors have no financial or personal relationships that could inappropriately influence this research.

Extraction of microbial genomic DNA. Microbial genomic DNA was extracted from suspended faeces and culture broth from the KUHIMM at 30 h, as described previously²¹. Purified DNA was eluted into TE buffer (10 mM TrisHCl, 1.0 mM EDTA) and stored at -20 °C until use.

Illumina library generation. Bacterial 16S rRNA genes (V3-V4 region) were amplified using genomic DNA as template and primers S-D-Bact-0341-b-S-17 (5'-CCTACGGGNGGCWGCAG-3') and S-D-Bact-0785-a-A-21 (5'-GACTACHVGGGTATCTAATCC-3')³⁸, as described previously¹³. Index primers (Nextera XT Index Kit; Illumina Inc., San Diego, CA, USA) overhanging the amplified sequences were added to the gene-specific sequences. The PCR reaction was performed according to the manufacturer's instructions. Amplicons were purified with AMPure XP DNA purification beads (Beckman Coulter, Brea, CA, USA) and eluted in 25 µL of 10 mM Tris (pH 8.5). Purified amplicons were quantified using an Agilent Bioanalyzer 2100 with DNA 1000 chips (Agilent Technology, Santa Clara, CA, USA) and Qubit 2.0 (Thermo Fisher Inc., Waltham, MA, USA), and pooled in equimolar concentration (5 nM). The 16S rRNA genes along with an internal control (PhiX control v3; Illumina) were subjected to paired-end sequencing using a Miseq sequencer (Illumina) with a Miseq reagent kit v3 (600 cycles; Illumina). The PhiX sequences were removed, and paired-end reads with Q scores ≥ 20 were joined using the software package MacQIIME version 1.9.1³⁹. The UCLUST algorithm⁴⁰ was used to cluster filtered sequences into OTUs based on a ≥ 97% similarity threshold. Chimeric sequences were checked and removed from the library using ChimeraSlayer⁴¹. Representative sequences from each OTU were taxonomically classified via the GreenGenes taxonomic database using the Ribosomal Database Project Classifier⁴². OTUs were

used for α -diversity estimation of the Chao1, Shannon diversity, and Simpson indexes. PCoA plots were calculated using OTUs from each sample based on unweighted UniFrac distances.

Real-time PCR. Real-time PCR to quantify total bacterial growth during cultivation was performed using a TP700 Thermal Cycler Dice Real Time System Lite (Takara Bio Inc., Ohtsu, Japan) with a primer set targeting all eubacteria²¹. The PCR reaction and amplification were performed as described previously²¹.

Measurement of SCFAs. Concentrations of SCFAs such as acetate, propionate, butyrate, lactate, and succinate were measured using a high-performance liquid chromatograph (HPLC; Shimadzu Corporation, Kyoto, Japan) equipped with an Aminex HPX-87H column (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and a RID-10A refractive index detector (Shimadzu Corporation). The HPLC was operated at 65 °C using 5 mM H₂SO₄ as the mobile phase with a flow rate of 0.6 mL/min.

Bioinformatics and statistical analyses. The various α -diversity values (Chao1, Shannon index, and Simpson index) were calculated using the MacQIIME software package³⁹ because they best fit the data distribution. PCoA was conducted using OTU information from each sample and calculated based on unweighted UniFrac distances⁴³ using MacQIIME. The nonparametric Kruskal-Wallis test, Dunnett test, and MANOVA were performed using JMP 13 software (SAS Institute Inc., Cary, NC, USA). $P < 0.05$ was considered statistically significant.

Data availability. All of the raw sequence data generated in this study have been deposited on the MG-RAST server⁴⁴ (<http://metagenomics.anl.gov>) as “Single Batch Fermentation System Simulating Human Colonic Microbiota_Indigestible Oligosaccharides” under accession numbers “mgm4757055.3–mgm4757122.3”.

References

- Gibson, G. R. *et al.* Dietary prebiotics: current status and new definition. *Food Sci. Technol. Bull. Funct. Foods* **7**, 1–19 (2010).
- Brownawell, A. M. *et al.* Prebiotics and the health benefits of fiber: Current regulatory status, future research, and goals. *J. Nutr.* **124**, 962–974 (2012).
- Slavin, J. Fiber and prebiotics: Mechanisms and health benefits. *Nutrients* **5**, 1417–1435 (2013).
- Barczynska, R., Kapusniak, J., Litwin, M., Slizewska, K. & Szalecki, M. Dextrins from Maize Starch as Substances Activating the Growth of Bacteroidetes and Actinobacteria Simultaneously Inhibiting the Growth of Firmicutes, Responsible for the Occurrence of Obesity. *Plant Foods Hum. Nutr.* **71**, 190–196 (2016).
- Carlson, J., Hospattankar, A., Deng, P., Swanson, K. & Slavin, J. Prebiotic Effects and Fermentation Kinetics of Wheat Dextrin and Partially Hydrolyzed Guar Gum in an *In Vitro* Batch Fermentation System. *Foods* **4**, 349–358 (2015).
- Noack, J., Timm, D., Hospattankar, A. & Slavin, J. Fermentation profiles of wheat dextrin, inulin and partially hydrolyzed guar gum using an *in Vitro* digestion pretreatment and *in Vitro* batch fermentation system model. *Nutrients* **5**, 1500–1510 (2013).
- Fenyvesi, É., Vikmon, M. & Szente, L. Cyclodextrins in Food Technology and Human Nutrition: Benefits and Limitations. *Crit. Rev. Food Sci. Nutr.* **56**, 1981–2004 (2016).
- Furune, T. *et al.* A study on the inhibitory mechanism for cholesterol absorption by α -cyclodextrin administration. *Beilstein J. Org. Chem.* **10**, 2827–2835 (2014).
- Sakurai, T. *et al.* Dietary alpha-cyclodextrin reduces atherosclerosis and modifies gut flora in apolipoprotein E-deficient mice. *Mol. Nutr. Food Res.* <https://doi.org/10.1002/mnfr.201600804> (2017).
- Van Geel-Schutten, G. H. *et al.* Biochemical and structural characterization of the glucan and fructan exopolysaccharides synthesized by the *Lactobacillus reuteri* wild-type strain and by mutant strains. *Appl. Environ. Microbiol.* **65**, 3008–3014 (1999).
- Sarbini, S. R. *et al.* *In vitro* fermentation of linear and alpha-1,2-branched dextrans by the human fecal microbiota. *Appl. Environ. Microbiol.* **77**, 5307–5315 (2011).
- Sarbini, S. R., Kolda, S., Deaville, E. R., Gibson, G. R. & Rastall, R. A. Potential of novel dextran oligosaccharides as prebiotics for obesity management through *in vitro* experimentation. *Br J Nutr.* **112**, 1303–1314 (2014).
- Sasaki, K. *et al.* Taurine does not affect the composition, diversity, or metabolism of human colonic microbiota simulated in a single-batch fermentation system. *PLoS One* **1–15** (2017).
- National Health and Nutrition Survey in Japan, 2015. *Ministry of Health, Labour and Welfare, Japan*, http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryuu/kenkou/kenkounippon21/en/eiyouchousa/koumoku_syokuhin_chousa.html (2015).
- Venema, K. & van den Abbeele, P. Experimental models of the gut microbiome. *Best Pract. Res. Clin. Gastroenterol.* **27**, 115–26 (2013).
- Long, W. *et al.* Differential responses of gut microbiota to the same prebiotic formula in oligotrophic and eutrophic batch fermentation systems. *Sci. Rep.* **5**, 13469 (2015).
- Payne, A. N., Zihler, A., Chassard, C. & Lacroix, C. Advances and perspectives in *in vitro* human gut fermentation modeling. *Trends Biotechnol.* **30**, 17–25 (2012).
- Rastall, R. A. Functional oligosaccharides: application and manufacture. *Annu. Rev. Food Sci. Technol.* **1**, 305–39 (2010).
- Eckburg, P. B. *et al.* Diversity of the human intestinal microbial flora. *Science (80-)*. **308**, 1635–8 (2005).
- Qin, J. *et al.* A human gut microbial gene catalog established by metagenomic sequencing. *Nature* **464**, 59–65 (2010).
- Takagi, R. *et al.* A single-batch fermentation system to simulate human colonic microbiota for high-throughput evaluation of prebiotics. *PLoS One* **11** (2016).
- Sender, R., Fuchs, S. & Milo, R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. *PLoS Biol.* **14** (2016).
- Morrison, D. J. & Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. *Gut Microbes* **7**, 189–200 (2016).
- Lefranc-Millot, C. *et al.* Impact of a Resistant Dextrin on Intestinal Ecology: How Altering the Digestive Ecosystem with NUTRIOSE(R), a Soluble Fibre with Prebiotic Properties, May Be Beneficial for Health. *J. Int. Med. Res.* **40**, 211–224 (2012).
- François, I. E. J. A. *et al.* Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: a double-blind, randomised, placebo-controlled, cross-over trial. *Br. J. Nutr.* **108**, 2229–2242 (2012).
- Olano-Martin, E., Mountzouris, K. C., Gibson, G. R. & Rastall, R. *In vitro* fermentability of dextran, oligodextran and maltodextrin by human gut bacteria. *Br. J. Nutr.* **83**, 247–255 (2000).
- Sarbini, S. R. *et al.* The prebiotic effect of α -1,2 branched, low molecular weight dextran in the batch and continuous faecal fermentation system. *J. Funct. Foods* **5**, 1938–1946 (2013).

28. Hobden, M. R. *et al.* *In Vitro* Fermentation of NUTRIOSE® FB06, a Wheat Dextrin Soluble Fibre, in a Continuous Culture Human Colonic Model System. *PLoS One* **8** (2013).
29. Kaewprasert, S., Okada, M. & Aoyama, Y. Nutritional effects of cyclodextrins on liver and serum lipids and cecal organic acids in rats. *J. Nutr. Sci. Vitaminol. (Tokyo)*. **47**, 335–9 (2001).
30. den Besten, G. *et al.* The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *J. Lipid Res.* **54**, 2325–2340 (2013).
31. Wrzosek, L. *et al.* Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. *BMC Biol.* **11**, 61 (2013).
32. Reichardt, N. *et al.* Phylogenetic distribution of three pathways for propionate production within the human gut microbiota. *ISME J* **8**, 1323–1335 (2014).
33. Martens, E. C., Koropatkin, N. M., Smith, T. J. & Gordon, J. I. Complex glycan catabolism by the human gut microbiota: The bacteroidetes sus-like paradigm. *Journal of Biological Chemistry* **284**, 24673–24677 (2009).
34. Salonen, A. *et al.* Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men. *ISME J* **8**, 2218–2230 (2014).
35. Flint, H. J., Scott, K. P., Louis, P. & Duncan, S. H. The role of the gut microbiota in nutrition and health. *Nat. Rev. Gastroenterol. Hepatol.* **9**, 577–589 (2012).
36. Fukuda, S. *et al.* Bifidobacteria can protect from enteropathogenic infection through production of acetate. *Nature* **469**, 543–547 (2011).
37. Fukuda, S., Toh, H., Taylor, T. D., Ohno, H. & Hattori, M. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. *Gut microbes* **3**, 449–454 (2012).
38. Klindworth, A. *et al.* Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. *Nucleic Acids Res.* **41**, 1–11 (2013).
39. Caporaso, J. G. *et al.* QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* **7**, 335–6 (2010).
40. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* **26**, 2460–2461 (2010).
41. Haas, B. J. *et al.* Chimeric 16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. *Genome Res.* **21**, 494–504 (2011).
42. Wang, Q., Garrity, G. M., Tiedje, J. M. & Cole, J. R. Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl. Environ. Microbiol.* **73**, 5261–5267 (2007).
43. Lozupone, C. & Knight, R. UniFrac: A new phylogenetic method for comparing microbial communities. *Appl. Environ. Microbiol.* **71**, 8228–8235 (2005).
44. Meyer, F. *et al.* The metagenomics RAST server – a public resource for the automatic phylogenetic and functional analysis of metagenomes. *BMC Bioinformatics* **9**, 386 (2008).

Acknowledgements

This work was supported by Japan Innovative Bioproduction Kobe (<http://www.org.kobe-u.ac.jp/bioproduction/>) and Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 17K12897. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

D.S., K.S., N.I. and R.O. designed the study. D.S., K.S. and N.I. performed the experiments, and T.Y. and I.F. analysed the data. D.S., K.S. and N.I. wrote the paper, A.K. and R.O. revised the manuscript.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-017-18877-8>.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017